First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
一线替雷利珠单抗联合化疗治疗程序性死亡配体1表达≥1%的晚期胃癌:RATIONALE-305研究的回顾性分析
期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03133-7
Moehler, Markus; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Lee, Keun-Wook; Rha, Sun Young; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Wyrwicz, Lucjan; Disel, Umut; Pazo-Cid, Roberto A; Fornaro, Lorenzo; Xu, Yaling; Sheng, Tao; Yang, Silu; Kadva, Alysha; Cruz-Correa, Marcia; Xu, Rui-Hua